References

Risk factors in head and neck cancer

10.1056/nejm198205133061905 · 1982 · External reference

Evidence for a causal association between human papillomavirus and a subset of head and neck cancers

10.1093/jnci/92.9.709 · 2000 · External reference

Molecular classification identifies a subset of human papillomavirus–associated oropharyngeal cancers with favorable prognosis

10.1200/jco.2004.00.3335 · 2006 · External reference

The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome

10.1016/j.radonc.2010.04.022 · 2010 · External reference

Human papillomavirus and survival of patients with oropharyngeal cancer

10.1056/nejmoa0912217 · 2010 · External reference

Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck–a systematic review and meta-analysis

10.1016/j.radonc.2011.03.004 · 2011 · External reference

Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes

10.1158/1078-0432.ccr-14-2481 · 2015 · External reference

Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma

10.1158/1078-0432.ccr-06-3047 · 2007 · External reference

Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer

10.1158/1535-7163.mct-09-1047 · 2010 · External reference

Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck

10.1002/ijc.11188 · 2003 · External reference

Serum biomarkers in head and neck squamous cell cancer

10.1001/jamaoto.2013.5688 · 2014 · External reference

Biology of vascular endothelial growth factor and its receptors in head and neck cancer: beyond angiogenesis

10.1002/hed.21588 · 2011 · External reference

Interleukin 4, interleukin 6 and osteopontin-serological markers of head and neck malignancy in primary diagnostics: a pilot study

10.3892/ol.2014.2312 · 2014 · External reference

Plasma tumor necrosis factor-alpha and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma

10.1007/s00432-014-1592-8 · 2014 · External reference

Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma

10.1016/j.oraloncology.2006.11.016 · 2007 · External reference

Plasminogen activator inhibitor-1 as regulator of tumor-initiating cell properties in head and neck cancers

2015 · External reference

Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer

10.1158/0008-5472.can-11-1182 · 2011 · External reference

Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study

10.3109/0284186x.2014.992547 · 2015 · External reference

FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial

10.1016/j.radonc.2012.09.015 · 2012 · External reference

An evaluation of multiplex bead-based analysis of cytokines and soluble proteins in archived lithium heparin plasma, EDTA plasma and serum samples

2016 · External reference

Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials

2016 · External reference

Scoring and classification of oropharyngeal carcinoma based on HPV-related p16-expression

10.1016/j.radonc.2012.09.017 · 2012 · External reference

Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck

10.1200/jco.2008.20.2853 · 2009 · External reference

Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization

10.1371/journal.pone.0051862 · 2012 · External reference

Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas

10.1016/j.radonc.2004.07.014 · 2004 · External reference

Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy

10.1158/1078-0432.ccr-03-0248 · 2004 · External reference

A proportional hazards model for the subdistribution of a competing risk

1999 · External reference

Pseudo-observations in survival analysis

10.1177/0962280209105020 · 2010 · External reference

Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials

10.3109/0284186x.2016.1167959 · 2016 · External reference

Serum prognostic markers in head and neck cancer

10.1158/1078-0432.ccr-09-2014 · 2010 · External reference

Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer

10.1158/1078-0432.ccr-11-2094 · 2012 · External reference

Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer

10.1016/j.oraloncology.2011.07.034 · 2011 · External reference

Dangers of using “optimal” cutpoints in the evaluation of prognostic factors

10.1093/jnci/86.11.829 · 1994 · External reference

A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5–85

10.1016/s0167-8140(97)00220-x · 1998 · External reference